MB 11040
Alternative Names: MB11040Latest Information Update: 30 Mar 2016
Price :
$50 *
At a glance
- Originator Mazence
- Developer KT&G Life Sciences
- Class Anti-inflammatories; Antineoplastics
- Mechanism of Action Immunomodulators; Toll-like receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Inflammation; Menopausal syndrome
Most Recent Events
- 30 Mar 2016 No recent reports on development identified - Phase-I for Menopausal syndrome and Cancer in South Korea (unspecified route)
- 28 Mar 2014 No development reported - Preclinical for Inflammation in South Korea (unspecified route)
- 31 Oct 2013 Phase-I clinical trials in Menopausal syndrome in South Korea (unspecified route)